Agenus Inc. (NASDAQ:AGEN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have received an average recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $14.50.

A number of brokerages have commented on AGEN. HC Wainwright reiterated a “buy” rating on shares of Agenus in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a report on Monday.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AGEN. Traynor Capital Management Inc. acquired a new position in shares of Agenus during the 3rd quarter worth approximately $50,000. Catalyst Funds Management Pty Ltd bought a new position in Agenus during the second quarter worth $50,000. Squarepoint Ops LLC acquired a new position in shares of Agenus in the third quarter valued at $54,000. Jump Financial LLC bought a new position in shares of Agenus in the second quarter valued at about $55,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Agenus during the 1st quarter worth about $58,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Stock Down 5.7%

AGEN stock opened at $3.31 on Wednesday. The business has a 50 day moving average price of $4.05 and a two-hundred day moving average price of $4.59. The company has a market cap of $112.57 million, a price-to-earnings ratio of -1.55 and a beta of 1.51. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $1.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The firm had revenue of $30.24 million during the quarter, compared to the consensus estimate of $80.39 million. On average, equities research analysts anticipate that Agenus will post -12.55 EPS for the current fiscal year.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.